AAPL317.31+1.99 (+0.63%) ▲|ABBV248.00-0.08 (-0.03%) ▼|ABT92.11-1.82 (-1.94%) ▼|ACN138.52+3.29 (+2.43%) ▲|ADBE230.61+6.97 (+3.12%) ▲|AMAT575.39-27.11 (-4.50%) ▼|AMD534.39-23.50 (-4.21%) ▼|AMGN360.45-2.94 (-0.81%) ▼|AMT169.50+0.91 (+0.54%) ▲|AMZN247.31+1.97 (+0.80%) ▲|AVGO384.05-15.92 (-3.98%) ▼|AXP354.43+3.85 (+1.10%) ▲|BA215.51-6.77 (-3.05%) ▼|BAC59.50-0.17 (-0.28%) ▼|BKNG175.80-2.59 (-1.45%) ▼|BLK1,031.56-4.55 (-0.44%) ▼|BMY59.34+1.76 (+3.06%) ▲|BNY151.27-0.65 (-0.43%) ▼|BRK-B496.85+3.14 (+0.64%) ▲|C140.71-0.08 (-0.06%) ▼|CAT931.47-20.94 (-2.20%) ▼|CL93.21+0.97 (+1.05%) ▲|CMCSA23.97+0.40 (+1.70%) ▲|COF203.02+1.50 (+0.74%) ▲|COP112.85+3.81 (+3.49%) ▲|COST926.43+10.18 (+1.11%) ▲|CRM171.22+7.90 (+4.84%) ▲|CSCO119.25-2.06 (-1.70%) ▼|CVS105.90+1.75 (+1.68%) ▲|CVX182.20+5.80 (+3.29%) ▲|DE585.64-1.22 (-0.21%) ▼|DHR200.16+1.11 (+0.56%) ▲|DIS96.00+0.38 (+0.40%) ▲|DUK126.86+1.38 (+1.10%) ▲|EMR135.38-3.50 (-2.52%) ▼|FDX313.74-0.95 (-0.30%) ▼|GD372.78-2.28 (-0.61%) ▼|GE353.42-5.85 (-1.63%) ▼|GEV1,042.60-48.97 (-4.49%) ▼|GILD131.40+1.57 (+1.21%) ▲|GM76.72-1.13 (-1.45%) ▼|GOOG350.67-4.36 (-1.23%) ▼|GOOGL352.51-4.67 (-1.31%) ▼|GS1,045.91-9.27 (-0.88%) ▼|HD337.11-6.19 (-1.80%) ▼|HON222.25-4.17 (-1.84%) ▼|IBM290.23+2.67 (+0.93%) ▲|INTC103.12-6.72 (-6.12%) ▼|INTU289.76+14.80 (+5.38%) ▲|ISRG407.12+0.34 (+0.08%) ▲|JNJ257.77+0.79 (+0.31%) ▲|JPM334.53-1.94 (-0.58%) ▼|KO84.25+0.76 (+0.91%) ▲|LIN524.06-5.73 (-1.08%) ▼|LLY1,181.87-6.71 (-0.56%) ▼|LMT520.68-2.54 (-0.49%) ▼|LOW207.70-3.93 (-1.86%) ▼|LRCX329.92-20.41 (-5.83%) ▼|MA537.70+10.96 (+2.08%) ▲|MCD272.61-1.99 (-0.72%) ▼|MDLZ59.86+1.03 (+1.75%) ▲|MDT83.57-0.30 (-0.36%) ▼|META656.73-12.48 (-1.86%) ▼|MMM157.70+0.18 (+0.11%) ▲|MO71.87+0.08 (+0.11%) ▲|MRK124.03+0.49 (+0.40%) ▲|MS221.09-1.19 (-0.54%) ▼|MSFT390.99+5.89 (+1.53%) ▲|MU937.00-42.30 (-4.32%) ▼|NEE88.38+0.42 (+0.48%) ▲|NFLX73.83+0.46 (+0.63%) ▲|NKE43.76-0.61 (-1.37%) ▼|NOW111.26+3.55 (+3.30%) ▲|NVDA203.53-7.43 (-3.52%) ▼|ORCL131.54-9.10 (-6.47%) ▼|PEP138.49+1.11 (+0.81%) ▲|PFE24.48+0.31 (+1.28%) ▲|PG148.37+1.33 (+0.90%) ▲|PLTR130.04+3.25 (+2.56%) ▲|PM180.19-1.43 (-0.79%) ▼|QCOM183.98-5.18 (-2.74%) ▼|RTX196.39+0.46 (+0.23%) ▲|SBUX107.34+1.33 (+1.25%) ▲|SCHW102.38-0.74 (-0.72%) ▼|SO96.47+0.86 (+0.90%) ▲|SPG219.49+0.72 (+0.33%) ▲|T21.55+0.42 (+1.99%) ▲|TMO528.51+1.46 (+0.28%) ▲|TMUS188.41+0.80 (+0.43%) ▲|TSLA394.76-13.00 (-3.19%) ▼|TXN298.57-12.89 (-4.14%) ▼|UBER74.26-0.28 (-0.38%) ▼|UNH429.09+4.47 (+1.05%) ▲|UNP289.13+2.17 (+0.76%) ▲|UPS112.89+0.42 (+0.37%) ▲|USB62.34-0.07 (-0.11%) ▼|V357.75+8.78 (+2.52%) ▲|VZ42.68+0.56 (+1.33%) ▲|WFC87.67+0.51 (+0.59%) ▲|WMT114.78+0.88 (+0.77%) ▲|XOM144.51+5.63 (+4.05%) ▲|AAPL317.31+1.99 (+0.63%) ▲|ABBV248.00-0.08 (-0.03%) ▼|ABT92.11-1.82 (-1.94%) ▼|ACN138.52+3.29 (+2.43%) ▲|ADBE230.61+6.97 (+3.12%) ▲|AMAT575.39-27.11 (-4.50%) ▼|AMD534.39-23.50 (-4.21%) ▼|AMGN360.45-2.94 (-0.81%) ▼|AMT169.50+0.91 (+0.54%) ▲|AMZN247.31+1.97 (+0.80%) ▲|AVGO384.05-15.92 (-3.98%) ▼|AXP354.43+3.85 (+1.10%) ▲|BA215.51-6.77 (-3.05%) ▼|BAC59.50-0.17 (-0.28%) ▼|BKNG175.80-2.59 (-1.45%) ▼|BLK1,031.56-4.55 (-0.44%) ▼|BMY59.34+1.76 (+3.06%) ▲|BNY151.27-0.65 (-0.43%) ▼|BRK-B496.85+3.14 (+0.64%) ▲|C140.71-0.08 (-0.06%) ▼|CAT931.47-20.94 (-2.20%) ▼|CL93.21+0.97 (+1.05%) ▲|CMCSA23.97+0.40 (+1.70%) ▲|COF203.02+1.50 (+0.74%) ▲|COP112.85+3.81 (+3.49%) ▲|COST926.43+10.18 (+1.11%) ▲|CRM171.22+7.90 (+4.84%) ▲|CSCO119.25-2.06 (-1.70%) ▼|CVS105.90+1.75 (+1.68%) ▲|CVX182.20+5.80 (+3.29%) ▲|DE585.64-1.22 (-0.21%) ▼|DHR200.16+1.11 (+0.56%) ▲|DIS96.00+0.38 (+0.40%) ▲|DUK126.86+1.38 (+1.10%) ▲|EMR135.38-3.50 (-2.52%) ▼|FDX313.74-0.95 (-0.30%) ▼|GD372.78-2.28 (-0.61%) ▼|GE353.42-5.85 (-1.63%) ▼|GEV1,042.60-48.97 (-4.49%) ▼|GILD131.40+1.57 (+1.21%) ▲|GM76.72-1.13 (-1.45%) ▼|GOOG350.67-4.36 (-1.23%) ▼|GOOGL352.51-4.67 (-1.31%) ▼|GS1,045.91-9.27 (-0.88%) ▼|HD337.11-6.19 (-1.80%) ▼|HON222.25-4.17 (-1.84%) ▼|IBM290.23+2.67 (+0.93%) ▲|INTC103.12-6.72 (-6.12%) ▼|INTU289.76+14.80 (+5.38%) ▲|ISRG407.12+0.34 (+0.08%) ▲|JNJ257.77+0.79 (+0.31%) ▲|JPM334.53-1.94 (-0.58%) ▼|KO84.25+0.76 (+0.91%) ▲|LIN524.06-5.73 (-1.08%) ▼|LLY1,181.87-6.71 (-0.56%) ▼|LMT520.68-2.54 (-0.49%) ▼|LOW207.70-3.93 (-1.86%) ▼|LRCX329.92-20.41 (-5.83%) ▼|MA537.70+10.96 (+2.08%) ▲|MCD272.61-1.99 (-0.72%) ▼|MDLZ59.86+1.03 (+1.75%) ▲|MDT83.57-0.30 (-0.36%) ▼|META656.73-12.48 (-1.86%) ▼|MMM157.70+0.18 (+0.11%) ▲|MO71.87+0.08 (+0.11%) ▲|MRK124.03+0.49 (+0.40%) ▲|MS221.09-1.19 (-0.54%) ▼|MSFT390.99+5.89 (+1.53%) ▲|MU937.00-42.30 (-4.32%) ▼|NEE88.38+0.42 (+0.48%) ▲|NFLX73.83+0.46 (+0.63%) ▲|NKE43.76-0.61 (-1.37%) ▼|NOW111.26+3.55 (+3.30%) ▲|NVDA203.53-7.43 (-3.52%) ▼|ORCL131.54-9.10 (-6.47%) ▼|PEP138.49+1.11 (+0.81%) ▲|PFE24.48+0.31 (+1.28%) ▲|PG148.37+1.33 (+0.90%) ▲|PLTR130.04+3.25 (+2.56%) ▲|PM180.19-1.43 (-0.79%) ▼|QCOM183.98-5.18 (-2.74%) ▼|RTX196.39+0.46 (+0.23%) ▲|SBUX107.34+1.33 (+1.25%) ▲|SCHW102.38-0.74 (-0.72%) ▼|SO96.47+0.86 (+0.90%) ▲|SPG219.49+0.72 (+0.33%) ▲|T21.55+0.42 (+1.99%) ▲|TMO528.51+1.46 (+0.28%) ▲|TMUS188.41+0.80 (+0.43%) ▲|TSLA394.76-13.00 (-3.19%) ▼|TXN298.57-12.89 (-4.14%) ▼|UBER74.26-0.28 (-0.38%) ▼|UNH429.09+4.47 (+1.05%) ▲|UNP289.13+2.17 (+0.76%) ▲|UPS112.89+0.42 (+0.37%) ▲|USB62.34-0.07 (-0.11%) ▼|V357.75+8.78 (+2.52%) ▲|VZ42.68+0.56 (+1.33%) ▲|WFC87.67+0.51 (+0.59%) ▲|WMT114.78+0.88 (+0.77%) ▲|XOM144.51+5.63 (+4.05%) ▲|

26.9 C

New York

Tuesday, July 14, 2026

Woven Woven Redefines Children’s Sleep Wellness with Innovative Bead-Free Weighted Blankets

Tineco’s World #1 Floor Cleaner Range Up To 46% Off For Amazon Prime Day

Focusing on On-Chain-Native Prediction Markets: BM Wallet Launches Prediction Markets, Reimagining the Web3 User Experience

Tag: innovation

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

Saint-Herblain (France), June 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive six-month antibody persistence and safety data for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ^®, in 304 children. Partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the European Union, the trial is intended to support a pivotal Phase 3 study in children, which the Company expects to initiate in the first quarter of 2026, with the objective of extending the product label to this age group.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsInnovation

Woven Woven Redefines Children’s Sleep Wellness with Innovative Bead-Free Weighted Blankets

Tineco’s World #1 Floor Cleaner Range Up To 46% Off For Amazon Prime Day

Focusing on On-Chain-Native Prediction Markets: BM Wallet Launches Prediction Markets, Reimagining the Web3 User Experience

Tag: innovation

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

Doral Renewables Partners with American Farmland Trust to Expand Smart Solar℠ Initiative

Warburtons Contributes $650,000 to Gate Project

Lytx Launches New Trust Center to Protect Commercial Fleets with Data Security, Privacy, and Transparency

IR Announces Enhanced Cisco Cloud Migration Support

Hyundai and Hyundai Hope on Wheels Present $200,000 to Children’s Hospital of Orange County (CHOC)

MarketsandMarkets’ 360Quadrants Recognizes Top Startups and SMEs in the Lubricants Identification Quadrant Report 2025

West Michigan based ESPEC North America, Inc. Joins Consumers Energy’s Renewable Energy Program

NOLA AI Unveils Breakthrough Atomic Speed Performance and Opens Private Beta

Oligonucleotide Synthesis Market worth US$24.7 billion by 2030 with 10.8% CAGR | MarketsandMarkets™

For The Record Launches Multi-Language Speech-to-Text; Overcomes Courtroom Language Barriers

“Ode to Freedom” Mural & Kufa Gallery

Conexwest Unveils 20ft Ground-Level Mobile Office Container with Integrated Restroom

Highlights in Oral Presentation of Mabwell’s 9MW2821 at 2025 ASCO

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us